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Abstract: Staphylococcus aureus is an important pathogen of both humans and animals, implicated 
in a wide range of infections. The emergence of antibiotic resistance has resulted in S. aureus strains 
that are resistant to almost all available antibiotics, making treatment a clinical challenge. 
Development of novel antimicrobial approaches is now a priority worldwide. Bacteria produce a 
range of antimicrobial peptides; the most diverse of these being bacteriocins. Bacteriocins are 
ribosomally synthesised peptides, displaying potent antimicrobial activity usually against bacteria 
phylogenetically related to the producer strain. Several bacteriocins have been isolated from 
commensal coagulase-negative staphylococci, many of which display inhibitory activity against S. 
aureus in vitro and in vivo. The ability of these bacteriocins to target biofilm formation and their novel 
mechanisms of action with efficacy against antibiotic-resistant bacteria make them strong 
candidates as novel therapeutic antimicrobials. The use of genome-mining tools will help to advance 
identification and classification of bacteriocins. This review discusses the staphylococcal-derived 
antimicrobial peptides displaying promise as novel treatments for S. aureus infections.  
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1. Introduction 
Staphylococcus aureus is a frequent opportunistic pathogen of humans and animals that is capable 
of causing a variety of infections including skin and soft tissue infections, mastitis, urinary tract 
infections (UTIs), osteomyelitis, meningitis, food poisoning, biofilm-associated infections or 
septicaemia [1–3]. These can range from trivial and self-limiting to severe and life-threatening. S. 
aureus is a leading cause of nosocomial infections, implicated in 30% of infectious endocarditis cases 
[4,5], and the second most common cause of hospital-acquired pneumonia [6,7]. However, S. aureus 
is also a commensal organism, with 20–30% of humans persistently colonised nasally by the bacteria 
[8–10]. There is an epidemiological link between nasal carriage of S. aureus and subsequent infection 
with the carriage strain, especially among hospitalised individuals [9,11]. Risk factors for S. aureus 
infection include prolonged hospitalisation (especially intensive care), surgery, orthopedic and 
nursing implants, compromised immunity, skin barrier defects, and inflammatory diseases such as 
atopic dermatitis. The pathogenicity of S. aureus is attributed to an array of virulence factors, which 
include toxins such as enterotoxins, exfoliative toxins, and Panton-Valentine leucocidin (PVL) [12,13]. 
S. aureus can cause disease in healthy individuals as a result of expression of these virulence factors 
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[1,13]. S. aureus also has the ability to form biofilms both on medically implanted devices and on 
tissue [14]; these characteristics allow S. aureus to invade tissue and disseminate, causing systemic 
disease. The emergence of antimicrobial resistance makes the treatment of S. aureus infections a 
clinical challenge, with many strains displaying methicillin-resistance (MRSA) or multidrug 
resistance (MDR) [15]. Methicillin-resistance is typically mediated by mecA, or less frequently by 
mecC, located on the staphylococcal chromosomal cassette mec (SCCmec), and is associated with 
resistance to virtually all β-lactam antibiotics [15–17]. Multidrug resistance is typically defined as 
acquired resistance to three or more classes of antibiotic, with some S. aureus strains possessing 
resistance to all available antibiotics [18]. Topical mupirocin application is often used to eradicate 
nasal MRSA colonisation pre-operatively to prevent infections, however there are reports of 
increasing mupirocin resistance [19]. As such, finding alternative treatments for MRSA infections is 
a public health priority worldwide [20].  
S. aureus, including MRSA, can be isolated from healthy and diseased animals, from companion 
animals to livestock [21–24]. S. aureus infection has serious welfare implications; some of the most 
severe infections can be seen in food animals, such as poultry, where the bacteria can cause comb 
necrosis, chondronecrosis and septicaemia [25,26], and in dairy cattle, where it is one of the causative 
agents of mastitis [27,28]. S. aureus causes chronic, sub-clinical intramammary infection in cattle, 
resulting in increased somatic cell count in the milk, and as such, decreased milk quality, in addition 
to decreased milk yield, increased veterinary and labour costs, and loss due to culling [27–29]. As a 
result, bovine mastitis is one of the most economically important diseases in animals. Colonisation 
and infection in animals also poses a threat to human health, so called livestock-associated MRSA 
(LA-MRSA), due to the risk of zoonotic transmission, via the food chain or through direct contact 
[30]. This represents the third recognised epidemiological form of human MRSA along with hospital-
associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA). Holistic approaches 
such as improved biosecurity on farms, vaccine development, and selective breeding for animals 
resistant to pathogens, have yet to succeed in the control of S. aureus infections in animals [31–35], 
increasing the urgent need for the development of novel antimicrobials. 
1.1. Bacteriocins as Novel Antimicrobials  
In recent years, the importance of the natural microbiota in health and disease has been 
highlighted [20,36–40]. In particular, the normal diverse healthy-state microbiota may help regulate 
inflammation and help prevent colonisation and invasion by potentially pathogenic organisms [41]. 
One of the ways by which commensal bacteria regulate colonisation by invasive pathogens is via 
bacteriocin production [20]. Bacteriocins are ribosomally synthesised peptides that display 
antimicrobial activity against bacteria closely related to the producer strain, but to which the 
producer strain itself is resistant [42,43]. Bacteriocin resistance genes are typically present 
concomitantly with bacteriocin structural genes. The mechanisms of resistance include antagonistic 
bacteriocin receptors or specialised ATP-binding cassette efflux transporters [43–45]. As the target 
strains and producer strains typically share an ecological niche, these specific resistance mechanisms 
contribute to producer strain survival [43,46–48]. Bacteriocin production is an important trait for 
bacterial fitness, allowing competition against other microorganisms within a niche [49]. However, 
bacteriocin activity is more complex, with some shown to act as signaling peptides in both quorum 
sensing systems or interaction with the host immune system [48,50,51]. Some bacteriocins are 
multifunctional, such as BacSp222 produced by Staphylococcus pseudintermedius 222, which features 
bacteriocin activity, cytotoxicity towards eukaryotic cells and immunomodulating properties [52]. 
The seeming ubiquity of bacteriocins, despite the energetic costs of production, supports the theory 
that they are important to bacterial success beyond their role as antimicrobial peptides, and up to 
99% of bacteria are thought to produce at least one bacteriocin [53]. Bacteriocins have become an 
important target in the search for novel antimicrobials as a result of their abundance and activity 
against a range of pathogens.  
Bacteriocins possess several advantages over traditional antibiotics as a treatment for bacterial 
infections. Firstly, they typically possess a very narrow spectrum of activity, resulting in less 
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disruption to the microbiota, which can increase susceptibility to pathogenic invasion and has been 
associated with several inflammatory or metabolic diseases [54]. Narrow spectrum antimicrobials 
also generate less selective pressure for the development of resistance in non-target organisms [55]. 
The mechanism of action of bacteriocins is distinct from most antibiotics, meaning they are effective 
against antibiotic-resistant strains of bacteria [56]. Many bacteriocins are also able to target quiescent 
cells as well as those actively dividing [57,58]. As ribosomally synthesised peptides, they are 
amenable targets for bioengineering, and can be modified relatively easily to improve characteristics 
such as potency, solubility, and stability [56,59]. They also show antimicrobial activity at very low 
concentrations compared to antibiotics (typically nanomolar concentrations) [46]. As peptides, they 
are susceptible to digestive enzymes; this improves their safety and minimizes disruption to the 
gastrointestinal microbiota but might limit them to parenteral or topical administration [54]. Several 
bacteriocins, such as nisin, have been approved for use as food bio-preservatives and granted 
generally regarded as safe (GRAS) status [60,61]. However, despite their use in the food industry, it 
is only recently that attention has been turned to potential use of bacteriocins as alternative 
antimicrobial therapies. Many Staphylococcus species have been shown to produce bacteriocins (Table 
1), although bacteriocin production is a strain-specific, not a species-specific, trait [62]. Coagulase-
negative Staphylococcus spp. (CoNS) are commonly found in the commensal skin microbiota [63]. As 
bacteriocins typically display antimicrobial activity against strains closely phylogenetically related or 
within the same niche as the producer, staphylococcal bacteriocins (referred to as staphylococcins) 
could be promising candidates for the treatment of S. aureus infections [64,65]. This review will 
explore fully and partially characterised staphylococcins, and their therapeutic potential as novel 
alternatives to traditional antimicrobials in the treatment of S. aureus infections.  
2. Staphylococcins 
A large number of bacteriocins have been isolated from Staphylococcus species. S. aureus is a 
prolific bacteriocin producer, with approximately 10 bacteriocins and bacteriocin-like inhibitory 
substances (BLIS) identified [46,66,67]. Six well-characterised bacteriocins have been isolated from 
Staphylococcus epidermidis [46,64,68–70]. Many other CoNS produce bacteriocins, and several have 
been shown to exert inhibitory activity against S. aureus, making them promising candidates for 
further research. Gram-positive bacterial derived bacteriocins tend to be highly cationic heat stable 
molecules [71,72]. Staphylococins are most commonly encoded on plasmids or other mobile genetic 
elements, although they can be chromosomally encoded [51,73].  
Gram-positive and Gram-negative bacteriocins have distinct classification systems; there are 
four classes of Gram-positive bacteriocins, each containing several sub-classes (Figure 1) [46,74]. The 
majority of staphylococcins belong to class Ia, also known as lantibiotics. These are small (<5 kDa), 
post-translationally modified peptides, containing lanthionine or β-methyllanthionine residues 
[43,71], and possess relatively broad spectrum activity for bacteriocins, typically demonstrating 
antimicrobial activity against a range of Gram-positive organisms [71]. Lantibiotics are the most 
extensively studied class of bacteriocins, and as a result, their mechanism of action is relatively well 
understood. The majority of lantibiotics cause bacterial cell lysis and death via membrane potential-
dependent permeabilisation or transmembrane pore formation [51,75,76]. The lantibiotic epidermin 
and its natural variant gallidermin can also inhibit peptidoglycan biosynthesis by binding 
membrane-bound lipid II, a peptidoglycan precursor [56,77–79]. These bacteriocins bind distinct sites 
from those targeted by the antibiotic vancomycin, allowing them to maintain efficacy against 
vancomycin-resistant bacterial strains [80]. The epidermin group of bacteriocins also have the 
potential to inhibit biofilm formation due to their ability to disrupt teichoic acid biosynthesis [75,81]. 
Pep5, a bacteriocin produced by S. epidermidis, binds negatively charged lipoteichoic acids, initiating 
autolysis of the target cell due to release and activation of cell wall hydrolysing enzymes [51]. This 
demonstrates that bacteriocins can inhibit target strains through several mechanisms, both 
bacteriostatic and bactericidal.  
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Figure 1. Classification of Gram positive-derived bacteriocins. 
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Subclass Ic, the sactibiotics, are extensively post-translationally modified bacteriocins 
characterised by the presence of cross-links between the thiol group of cysteine residues and the α-
carbon of acceptor amino acids [42,82]. Only a handful of sactibiotics have been characterised, nearly 
all from Bacillus spp. However the first staphylococcal-derived sactibiotic, hyicin 4244, was recently 
discovered by Freitas De Souza Duarte et al. [83]. Many of the first described sactibiotics were circular, 
leading to the initial classification of sactibiotics as class IV [84]. However, the existence of linear 
sactibiotics has resulted in some discrepancy regarding the position of sactibiotics within bacteriocin 
nomenclature; it has been suggested they represent a novel class, class V, but currently they are 
tentatively considered a subgroup of class I [84,85]. As more sactibiotics are isolated and 
characterised, a robust classification of these substances may be elucidated.  
The remaining classes of bacteriocin are not as well characterised as the class I peptides. Class 
II, compromised of four subclasses, contains fewer members than seen in class I. Most belong to class 
IId; linear, single chain peptides, typically unmodified and of molecular mass below 10 kDa [66]. 
Class IIb contains bacteriocins composed of two chains. These bacteriocins can be further defined as 
type E, where both components show inhibitory activity alone but the presence of both enhances this 
activity. However, the two class IIb staphylococcins (C55 and aureocin A70 both produced by S. 
aureus) are type S (synergy) meaning that both chains must be present in equimolar proportions for 
bacteriocin activity [46,72].  
Class III bacteriocins are large (>10 kDa), heat-labile proteins in two sub-classes; IIIa, the 
bacteriolytic enzymes, and IIIb, non-lytic enzymes [81,86]. The in vitro and in vivo efficacy of 
lysostaphin, a class IIIa metalloprotease, against a range of pathogens has been studied since the 
1960s [87]. The catalytic domain of lysostaphin has three distinct functions (a glycylglycine 
endopeptidase, an endo-B-N-acetyl glucoamidase, and an N-acetyl-muramyl-L-alanine amidase) 
allowing it to hydrolyse peptidoglycan components, particularly pentaglycine cross-links [88,89]. 
These are not typically seen in CoNS, making lysostaphin specific for actively growing and quiescent 
S. aureus [88–90].  
Class IV is the final class of staphylococcins. These bacteriocins are poorly characterised and 
complex proteins, containing carbohydrate or lipid moieties [46,91]. Currently there is only one 
known staphylococcin in this group; aureocyclicin 4185, isolated from S. aureus 4185. This is a cyclic 
bacteriocin, thought to be cationic, with high hydrophobic residue content. There is little known 
about its mechanism of action or spectrum of activity [91].  
Whilst several staphylococcins have been well characterised (Table 1), there are also many other 
that are only partially characterised with undefined structures, genetics and activities. Few have been 
tested for antimicrobial activity against pathogens, although some produced by CoNS have shown 
promising anti-S. aureus activity in vitro and in vivo. 
2.1. Studies Showing in vitro Inhibitory Activity against Staphylococcus aureus.
Antibiotics 2020, 9, 40 6 of 18 
Table 1. Well-characterised bacteriocins isolated from Staphylococcus species. 
Class Subclass Subtype Bacteriocin Producing Strain Inhibits S. aureus: Strain (MIC) in vivo Model References 
I Ia A1 BacCh91 * S. aureus CH9/DSM26258 
in vitro: ATCC25923, Newman, M-122, RN4220 
(4.0–6.0 μM) 
 [92] 
   Epicidin 280 * S. epidermidis BN280   [70] 
   Epidermin * S. epidermidis Tü3298 in vitro  [74,93] 
   Epilancin 15X * S. epidermidis 15X154   [94] 
   Epilancin K7 * S. epidermidis K7   [69] 
   Gallidermin * S. gallinarum F16/P57 Tü3298 in vitro: ATCC29213, CCUG35601 (1.25–8.0 μg/mL)   [75,95,96] 
   Hominicin S. hominis MBBL2–9 
in vitro: ATCC25923, ATCC11435, CCAR M3501 
(0.06–3.82 μg/mL)  
 [97,98] 
   Hyicin 3682 S. hyicus 3682 in vitro  [99,100] 
   Nisin J S. capitis APC2923 in vitro  [20] 
   Pep5 S. epidermidis 5 in vitro  [73,74,93] 
  A2 Nukacin ISK-1 ** 
S. warneri Nukadoko/S. simulans 
3299 
  [101] 
   Warnericin RB4 S. warneri RB4   [102] 
 Ic  Hyicin 4244 S. hyicus 4244 in vitro  [83,103] 
II IIb S Aureocin A70 S. aureus A70   [104] 
  S C55 * S. aureus C55   [67] 
 IId  Aureocin A53 * S. aureus A53   [66,74] 
   BacSp222 ** S. pseudintermedius 
in vitro: DSM26258, MRSA USA300, KB/8568, 
ATCC25923 (0.89–1.30 μM) 
 [52] 
Class Subclass Subtype Bacteriocin Producing Strain Inhibits S. aureus: Strain (MIC) in vivo Model References 
II IId  Capidermicin S. capitis CIT060  
in vitro: NCDO1499, DPC5297, Newman, RF122 
(3.1–10 μg/mL) 
 [105] 
   Epidermicin NI01 * S. epidermidis 224 
in vitro: 1195, MRSA s37, MRSA s41, MRSA s71 
(1.0–2.0 μg/mL) 
greater wax 
moth, cotton rat  
[64,106,107] 
III IIIa  
Endopeptidase 
ALE-1 † 
S. capitis EPk1   [108] 
   Lysostaphin ** 
S. simulans biovar Staphylolyticus 
ATCC1362 






IV   Aureocyclicin 4185 S. aureus 4185   [91] 
Chemical structure available from: * www. http://bactibase.hammamilab.org; ** https://www.ncbi.nlm.nih.gov/Structure; † https://www.rcsb.org; all other chemical 
structures available from references stylised in bold. 
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Multiple techniques have been used to screen bacterial isolates for bacteriocin production in 
vitro. These include spot-on lawn assays where test producer strains are pipetted in small volumes 
onto the surface of agar plates, which are overlaid with soft agar containing the indicator (target) 
strain. Well-diffusion assays can be carried out using whole bacteria or, more commonly, cell-free 
supernatants [74,120]. The limitation of these assays is that they cannot discriminate between 
inhibitory activity due to bacteriocins or other antimicrobial substances, such as phenol-soluble 
modulins or organic acids [51]. The use of whole live bacteria also limits the quantitative data that 
can be obtained, as these assays cannot provide a minimum inhibitory or bactericidal concentration 
(MIC/MBC). Some studies utilise inhibition zone or density measurements to calculate arbitary units 
(AU) of inhibition, however these measurements are hard to standardise and are of less value than 
MICs. Partially purified protein and peptide antimicrobial substances are often tested for stability 
and activity under different conditions, such as pH, temperature and following proteolytic digestion 
by enzymes such as proteinase K or trypsin. Proteolysis-associated loss of activity confirms their 
protein or peptide structure [43]. Based on these results it is then reasonable to presume the 
antimicrobial substance is a bacteriocin-like inhibitory substance (BLIS), however, molecular and 
genomic analysis should be carried out to confirm the molecule is a bacteriocin and further 
characterise and classify it.  
The lantibiotics Pep5 and epidermin, both produced by Staphylococcus epidermidis, were shown 
to inhibit 14 and 13 of 16 test strains of S. aureus, respectively, including the endemic Brazilian MRSA 
clone A/22C. Pep5 also inhibited a mupirocin-resistant strain [74]. Further studies showed that Pep5 
inhibited 63% and epidermin 87% of 165 S. aureus isolates from bovine mastitis cases in South 
America [85]. Hyicin 3682 from S. hyicus, a member of the epidermin-like group, inhibited 15 of 16 S. 
aureus test strains [99,100]. Hominicin from S. hominis displayed potent activity against multiple 
strains including S. aureus ATCC 25923, MRSA ATCC 11435, and vancomycin-intermediate S. aureus 
CCARM 3501 [97,98], at MICs of 0.06μg/mL, 0.96 μg/mL, and 3.82 μg/mL, respectively [98]. BacCh91, 
produced by S. aureus CH91, inhibited four test strains of S. aureus (ATCC25293, Newman, M-122 
and RN4220), with an MIC of 4.0–6.0 μM [92]. Gallidermin, isolated from poultry-associated 
Staphylococcus gallinarum, has been shown to be bactericidal against both MRSA and methicillin-
sensitive S. aureus (MSSA) [96,121]. Gallidermin demonstrated both an MIC and MBC of 1.25 μg/mL 
against MSSA, and 1.56 μg/mL against MRSA [96]. Gallidermin was also able to inhibit biofilm 
formation of S. aureus SA113 at 0.16× the MIC [75]. Biofilm inhibition by gallidermin is due to 
repression of biofilm related genes atl and ica, encoding autolysin and polysaccharide intercellular 
adhesin (PIA), respectively. These gene products are involved in attachment to surfaces and cell 
aggregation, important steps in biofilm formation. However, gallidermin was not as effective against 
pre-formed biofilms, requiring 8× MIC to display inhibitory activity with 0.1–1.0% ‘persister’ cells 
still remaining [75]. The activity against planktonic cells and biofilm formation at low concentrations 
combined with the absence of cytotoxicity against fibroblasts or peripheral blood mononuclear cells, 
suggests gallidermin is a promising candidate as a therapeutic antimicrobial agent. 
Recently, a natural variant of the lantibiotic nisin (nisin J) was isolated from Staphylococcus capitis 
APC2923 [122]. Nisin is a well-characterised bacteriocin first isolated from Lactococcus lactis; there are 
now at least ten known natural nisin variants produced by various Lactococcus, Streptococcus and 
Blautia spp. [123–128]. Nisin J appears resemble streptococcal nisin variants more closely than 
lactococcal variants [122]. Nisin J inhibited staphylococcal isolates, including S. aureus, with greater 
efficacy than nisin A or Z [122]. Like other nisin variants, the nisin J-encoding gene cluster resides on 
a plasmid; this has led to the suggestion that the gene cluster has been acquired via horizontal gene 
transfer, possibly explaining why nisin variants are isolated from several species [122]. 
A bacteriocin produced by Staphylococcus hyicus 4244 (hyicin 4244) was shown to have inhibitory 
activity against other staphylococcal species [83]. This bacteriocin inhibited ten clinical S. aureus 
isolates from humans and cattle, and demonstrated efficacy against MRSA and MDR strains. Hyicin 
4244 also showed potential as an S. aureus biofilm-inhibiting agent. Genome analysis and further 
characterisation showed it belonged to class Ic, the sactibiotics [103], the first staphylococcin in this 
subclass.  
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BacSp222 is a class II staphylococcin produced by S. pseudintermedius [52]. This tryptophan 
residue rich bacteriocin showed no resemblance in peptide sequence to other bacteriocins beyond 
limited similarities to class II bacteriocins such as epidermicin NI01 and lacticin Q and Z. BacSp222 
inhibited four S. aureus test strains, including MRSA and S. aureus CH91, the producer strain of 
bacteriocin BacCH91, with an MIC of 0.89–1.30 μM. BacSp222 possesses some unusual characteristics 
for a bacteriocin; it is resistant to protease digestion and is active against the producer strain, although 
the MIC required (2.1 μM) was much higher than the MIC against a non-producer S. pseudintermedius 
strain (0.16 μM). Capidermicin and epidermicin NI01 are also class II bacteriocins, both belonging to 
the aureocin A53-subgroup [64,105]. Capidermicin inhibited all four test strains of S. aureus 
(NCDO1499, DPC5297, Newman, and RF122) with an MIC of 3.1–10 μg/mL, as well as S. 
pseudintermedius (MIC 10 μg/mL) [105]. Epidermicin NI01 inhibited MRSA in vitro and was not toxic 
to erythrocytes or dermal fibroblasts, even at a concentration of 100× the MIC [64], making 
epidermicin NI01 a promising candidate treatment for S. aureus and S. pseudintermedius infections. 
The latter being a prominent pathogen in companion dogs, particularly in pyoderma [129], with 
antimicrobial resistance, including methicillin-resistance and MDR isolates presenting a challenge to 
treatment [130–132]. As with S. aureus, bacteriocins and related products may have a valuable role in 
new approaches to tackle this pathogen. 
Many studies have demonstrated the efficacy of lysostaphin against S. aureus. Zygmunt et al. 
[114] showed lysostaphin inhibited 16 MRSA isolates with 4–8× the potency of synthetic β-lactams. 
Lysostaphin inhibited 111 clinical MRSA isolates in a study by Huber and Huber [116], with a 
subsequent study by von Eiff et al. [90] showing inhibition of 429 MRSA and MSSA strains, isolated 
from both commensal nasal swabs and cases of bacteraemia. Lysostaphin was also shown to kill 
biofilm-associated S. aureus cells and disrupt the biofilm extracellular matrix [115]. Catheters coated 
with lysostaphin showed complete clearance of S. aureus compared to control catheters, where an 
average of 493 CFU were recovered. The inhibitory activity of lysostaphin was maintained on the 
catheters for at least four days post-coating, suggesting lysostaphin is able to bind to plastic surfaces 
and retain anti-staphylococcal activity for several days [111]. Due to this, lysostaphin has potential 
use as a preventative and treatment for biofilm-associated infections. The promising inhibitory 
activity of lysostaphin against S. aureus led to investigations of its efficacy in vivo.  
2.2. Models of in vivo Bacteriocin Therapy for Staphylococcus aureus Infection  
Animals are often used as models of human disease to determine the safety and efficacy of 
treatments under physiological conditions [133]. Lysostaphin has been widely tested in a range of in 
vivo systems. A single intravenous injection of lysostaphin decreased S. aureus bacterial load and 
increased survival rates in rodent models of infection, including mastitis, peritonitis and sepsis [117–
119]. In mouse models of renal disease, a single intravenous dose of lysostaphin (from 1.56 mg/kg to 
50 mg/kg) significantly reduced viable S. aureus bacterial counts from renal lesions by 95% compared 
to an untreated control [112], whilst another study showed a 39–78% reduction in S. aureus bacterial 
burden and a 55–65% decrease in mortality, dependent on the dose [113]. Rabbit models were used 
to test the efficacy of lysostaphin against S. aureus associated aortic valve endocarditis [88,109]. Both 
studies demonstrated a reduction in S. aureus counts following administration of lysostaphin, with a 
single dose showing a 3.7–6.63 log10 and 7.27–8.5 log10 CFU/g decrease in bacterial counts compared 
to antibiotic-treated and untreated controls, respectively [88,109]. In one case, this result was seen 
three days post-treatment [109] whilst the second study noted that by 30 h post-treatment there was 
no difference in S. aureus counts between treated and control animals [88]. It is possible that the choice 
of vehicle and route of administration affects the duration of lysostaphin activity in vivo; this was 
further highlighted in a cotton rat model of S. aureus colonisation of the nares, where 0.5% lysostaphin 
in a petroleum-based vehicle eradicated MRSA and MSSA in 93% of subjects whilst lysostaphin in a 
PBS solution resulted in eradication in only 33% [57]. There has been a single trial of lysostaphin to 
eradicate nasal colonisation in humans comparing three treatment groups with an intranasal spray 
of 0.5% lysostaphin in saline 3 × daily for five days, intranasal neomycin/polymyxin B/bacitracin 
spray 3 × daily for five days, or no treatment [110]. 40% of the lysostaphin-treated group were cleared 
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of S. aureus colonisation, compared to 6% of the antibiotic-treated and 3% of the untreated group. The 
effect of lysostaphin appeared to be transient, however, with re-colonisation seen by Day 11. It is 
possible that if delivered in a different vehicle, a longer-lived effect may be seen and this is a 
promising direction for further studies.  
A relatively new model has been introduced for first-line in vivo testing, using Galleria mellonella 
(greater wax moth) larvae. These are an alternative to mammalian models as their immune system 
shows a high degree of structural and functional similarities to mammals [134]. These models are 
more accessible, inexpensive and ethical than using experimental mammals [106]. This model was 
used to test the efficacy and safety of epidermicin NI01 for S. aureus infection, which was non-toxic 
to the larvae and increased survival compared to untreated controls [106]. However, no quantified 
data for S. aureus bacterial burden before and after treatment was provided, which would be helpful 
in understanding its efficacy as an antimicrobial agent. Epidermicin NI01 was also tested in a cotton 
rat model of S. aureus nasal colonisation [107]; the nares of cotton rats structurally resemble those of 
humans, making it a useful model [135]. Subjects were treated with a single dose of 0.8% epidermicin 
NI01, twice daily treatment for three days with 0.04% epidermicin NI01, 0.2% epidermicin NI01, 2% 
mupirocin, or a vehicle control. A single dose of 0.8% epidermicin NI01 was most effective, resulting 
in a significant reduction in nasal MRSA burden and eradication in three of five test subjects [107]. 
Epidermicin NI01 is therefore a potential novel therapeutic for S. aureus nasal colonisation.  
3. Other Antimicrobial Substances with Anti-Staphylococcus aureus Activity  
3.1. Bacteriocin-Like Inhibitory Substances 
A partially purified antimicrobial substance has been derived from Staphylococcus pasteuri RSP-
1 [65]. Cell-free supernatant (CFS) from S. pasteuri RSP-1 was found to inhibit 11 out of 14 S. aureus 
test strains [65]. Live-dead assays suggest this substance is bactericidal, causing membrane damage 
and subsequent cell death in target cells. Antimicrobial activity of the CFS was lost following 
proteolytic digestion, whilst nuclease, amylase and lipase had no effect, confirming the substance is 
proteinaceous. It was heat stable up to 121 °C and at a range of pH, although a gradual loss of activity 
was seen with increasing pH. These characteristics are suggestive of a bacteriocin. The substance, 
named pasteuricin, has a molecular weight of 5 kDa [65], suggesting it belongs to bacteriocin class I 
or II, but further characterisation is needed. 
Staphylococcus capitis TE8 isolated from the skin microbiota of humans showed antimicrobial 
activity against a range of Gram-positive organisms, including S. aureus, but had no effect on Gram-
negative organisms [136]. Partially purified CFS extract also demonstrated this activity, which was 
lost with proteinase K digestion, suggesting the inhibitory effect was mediated by production of a 
BLIS. Genomic analysis revealed S. capitis TE8 possesses multiple antimicrobial peptide (AMP) gene 
clusters, including those encoding an epidermicin-like peptide, a gallidermin-like peptide, and 
several phenol-soluble modulins [136]. The epidermicin-like peptide seen may be capidermicin, an 
epidermicin variant recently isolated from S. capitis CIT060 [105]. However, it is possible that the BLIS 
and gene-clusters possessed by S. capitis TE8 are novel bacteriocins.  
Nakatsuji et al. [62] explored the abundance of AMP production in the skin microbiota of humans 
with atopic dermatitis (AD) and healthy controls; they found that AMPs were common in the 
microbial communities of healthy subjects, but not those with AD. The application of AMP-
producing S. hominis or S. epidermidis to the skin of AD subjects significantly decreased S. aureus 
burden on the skin compared to untreated and vehicle-treated controls, supporting the protective 
role of AMP-producing CoNS within the skin microbiota. Further investigation of commensal CoNS 
isolates revealed a strain of S. hominis (A9) with potent antimicrobial activity against S. aureus. 
Application of S. hominis A9 to sanitised pig skin coated with 1 × 105 CFU/cm2 S. aureus or to mice 
colonised with S. aureus significantly decreased S. aureus counts, with application twice daily for one 
week eliminating S. aureus colonisation in the mouse model. In contrast, application of killed S. 
hominis A9 or a non-inhibitory control strain of S. hominis had no effect. Genomic and biochemical 
analysis revealed S. hominis A9 produces two AMPs, predicted to be lantibiotics based their on 
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structure and amino acid composition. These AMPs, named Sh-lantibiotic-α and Sh-lantibiotic-β, 
were encoded within a gene cluster containing lanM, lanC, and lanT homologs. These genes were not 
detected in non-inhibitory S. hominis strains. Purified Sh-lantibiotic-α and Sh-lantibiotic-β inhibited 
S. aureus on sanitised pig skin at a concentration of 0.5 nM, whilst concentrations up to 10 nM had no 
effect on S. hominis A9, the producer strain. Sh-lantibiotic-α and Sh-lantibiotic-β were able to suppress 
clinical S. aureus isolates, including MRSA USA300, but had no effect on commensal species isolated 
from the skin such as Propionibacterium acnes, S. epidermidis, and Corynebacterium minutissimim. This 
potent anti-S. aureus activity with limited disruption to microbiota make Sh-lantibiotic-α and Sh-
lantibiotic-β promising candidates for further development as novel therapeutics for S. aureus 
infection in AD and other skin conditions.  
3.2. Inhibitory Staphylococcal Strains  
Several strains of CoNS inhibit S. aureus in agar-based antagonism assays. Although the 
antimicrobial substances responsible have not been isolated, most are presumed to be BLIS. 
Staphylococcus succinus AAS2 CFS potently inhibited S. aureus in well-diffusion assays [137]. Another 
study [138] found that 28 of 243 Staphylococcus isolates produced antimicrobial substances; all were 
susceptible to proteolytic digestion and thus classified as BLIS. BLIS-producing isolates included S. 
chromogenes, S. epidermidis, S. haemolyticus, S. pseudintermedius, S. aureus, and S. agnetis. All the BLIS-
producing isolates harboured nukA or bsaA2 genes, suggesting these BLIS are related to nukacin ISK-
1 or Bsa (a member of the epidermin-like lantibiotics). Purification, classification, and further testing 
of the inhibitory activity against S. aureus is needed to determine their potential as anti-S. aureus 
agents. 77 of 89 Staphylococcus isolates from nasal swabs of 37 human volunteers were shown to have 
inhibitory activity [139]. These isolates belonged to six species: S. epidermidis, S. aureus, S. hominis, S. 
lugdunensis, S. warneri, and S. capitis. Only two of the total 77 strains, however, showed inhibitory 
activity against S. aureus. 96% of the S. epidermidis strains produced BLIS, but these were not further 
investigated to determine if they were novel or one of the already isolated bacteriocins from this 
species. A recent study demonstrated AMP production by 21 CoNS strains, belonging to five species; 
S. capitis, S. hominis, S. simulans and S. warneri [20]. Of these, four S. warneri strains and one S. hominis 
strain were able to inhibit S. aureus [20]. Two strains belonging to S. capitis, APC2934 and APC2918, 
were able to inhibit both S. aureus and MRSA test strains [20]. These strains did not possess the 
structural genes encoding nisin J and colony mass spectrometry did not match the peptides produced 
by these S. capitis strains to any listed on BACTIBASE [20], suggesting these are potentially novel 
bacteriocins. 
Carson et al. [140] investigated 441 non-aureus staphylococci (NAS) isolates; 40 of the isolates 
showed inhibitory activity against a bovine mastitis S. aureus strain; of these, 23 also inhibited MRSA. 
These strains belonged to S. capitis, S. chromogenes, S. epidermidis, S. pasteuri, S. simulans and S. xylosus. 
Only five of these species inhibited S. aureus in well-diffusion assays using chloroform-extracted cell-
free supernatant; all five supernatants were inactivated by proteinase K, suggesting the active 
components are BLIS secreted by the bacteria. The genomes of the 441 NAS were studied for the 
presence of bacteriocin biosynthetic gene clusters. 105 clusters were identified from 95 NAS isolates, 
belonging to 16 species (Table 2), but there was no obvious clustering based on phylogeny or 
bacteriocin class. Ten of the NAS genomes encoded two clusters, belonging to different classes, 
suggesting these isolates have the potential to produce two bacteriocins [140]. This data shows that 
the 95 isolates possessing bacteriocin gene clusters have the potential to produce bacteriocins. 
However, only 40 of the isolates displayed inhibitory activity in vitro. The discrepancy between 
presence of bacteriocin genes and production of bacteriocins is likely due to the influence of growth 
conditions on bacteriocin production; the availability of nutrients, presence of stressors, temperature, 
and choice of media can all affect bacteriocin production [20]. This highlights the importance of 
screening methods when trying to identify bacteriocin-producing bacteria, suggesting that there may 
be many more strains capable of producing bacteriocins that have not yet been discovered. Genome-
mining tools, such as antiSMASH and BAGEL [141,142], are able to identify bacteriocin gene clusters 
in bacterial genomes, highlighting those harbouring the potential to produce bacteriocins. These 
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techniques will be invaluable in the search for novel bacteriocins especially as the availability of 
sequenced genomes increases.  
Table 2. Strains of Staphylococcus found to harbour bacteriocin gene-clusters from 441 non-aureus 
Staphylococcus isolates analysed, the number of isolates possessing bacteriocin production genes that 
displayed inhibitory activity, and the number of isolates displaying in vitro inhibitory activity against 
S. aureus strains isolated from bovine mastitis cases. Each cluster encodes one bacteriocin [140]. 
 
 Class I  Class II 
Lantibiotics Sactibiotics Lasso Peptides  
Number of Bacteriocin Clusters Identified 29 3 4 69 
Number of Isolates that the Clusters are 
Present in 29 3 2 68 
The Species that the Clusters are Present in 
S. capitis 
S. capitis 




S. cohnii S. haemolyticus  
S. epidermidis S. hyicus 
S. equorum S. saprophyticus 
S. gallinarum S. sciuri 
S. sciuri S. simulans 
S. simulans S. succinus 
S. succinus S. warneri 
S. vitulinus S. xylosus 
Number of Isolates Showing Inhibitory 
Activity in vitro 15 2 1 9 
3.3. Staphylococcal-Produced Antimicrobial Substances  
Staphylococcus species produce a range of other secretory-AMPs (sAMPs) alongside bacteriocins, 
and several of these non-bacteriocin AMPs show promise as therapeutic agents for S. aureus 
infections. Esp is a serine protease produced by some S. epidermidis strains [143]. It was noted that 
presence of certain S. epidermidis strains within the nasal cavity appeared to influence S. aureus nasal 
colonisation. The CFS of these strains inhibited S. aureus in vitro, leading to the purification and 
identification of Esp. Application of purified Esp or Esp-producing S. epidermidis to the nasal cavities 
of S. aureus carriers eliminated S. aureus colonisation. Esp is effective against S. aureus biofilms, 
cleaving autolysin-derived murein hydrolases [144] and preventing the release of DNA, one of the 
structural components of S. aureus biofilm extracellular matrices [145,146]. Esp also targets S. aureus 
surface proteins, disrupting host-pathogen interactions [147], allowing Esp to be active against 
biofilm-forming and planktonic S. aureus cells. This suggests Esp could be a very promising 
antimicrobial agent.  
Lugdunin is a novel antimicrobial, isolated from S. lugdunensis IVK28 [148]. It is only produced 
under iron-limiting conditions on solid agar, again highlighting the importance of growth conditions 
of producer strains when isolating antimicrobial substances. Lugdunin was encoded by all the S. 
lugdunensis strains analysed, suggesting production is species specific rather than strain specific [148]. 
Lugdunin is a complex, non-ribosomally synthesised peptide, containing a tryptophan moiety, with 
no resemblance to any known antimicrobial substances [148]. Lugdunin became the founding 
member of a new class of antibiotics, the thiazolidine-containing peptide antibiotics. It is suggested 
that it exerts its antimicrobial activity by depleting bacterial energy resources [148]. Lugdunin 
demonstrated potent inhibitory activity against a range of Gram-positive organisms, including 
MRSA and glycopeptide-intermediate S. aureus [148]. This antibiotic displayed no toxicity towards 
human neutrophils or erythrocytes, and retained activity in human serum. Lugdunin was also able 
to reduce or eradicate S. aureus in a mouse model [148]. Together these examples demonstrate the 
range of antimicrobial substances produced by commensal staphylococci, and their potential as novel 
treatments for S. aureus infection. It is highly likely more remain to be discovered.  
4. Conclusions and Future Directions 
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The commensal bacteria residing in the microbiota play a vital role in protecting the host from 
invasion of pathogenic organisms. This protective activity is often mediated by bacteriocins, which 
are ribosomally synthesised peptides produced by bacteria that possess antimicrobial activity. 
Bacteriocins may be a valuable tool in the future fight against antimicrobial-resistant pathogens due 
to their novel mechanisms of action, narrow spectrum of activity, and ability to be bioengineered to 
improve specific qualities desirable in biopharmaceutical agents. Many bacteriocins produced by 
staphylococci display potent activity against S. aureus in vitro; however, the lack of cytotoxicity 
testing of many bacteriocins is a limitation when assessing their therapeutic usefulness. Although 
many bacteriocins demonstrate cytotoxicity against eukaryotic cells, often in a dose-dependent 
manner, this does not entirely eliminate their potential as candidates for treatment of S. aureus 
infections including those caused by methicillin-resistant strains in humans and animals. Thorough 
evaluation of potential cytotoxic effects and pharmacodynamics of the substance, weighed against its 
efficacy, is required to determine suitability as an anti-S. aureus agent. Genome-mining techniques 
will facilitate the search for bacteriocin-producing bacterial strains, overcoming some of the 
limitations of agar assay-based methods, and helping eliminate some discrepancy in the classification 
of these substances.  
Elucidation of the mechanisms of action of bacteriocins, especially those belonging to classes II-
IV, alongside further testing of their efficacy under physiological conditions is required to determine 
their suitability for therapeutic use. It is important to note that although resistance among target 
strains to these peptides has yet to be witnessed under laboratory conditions, resistance mechanisms 
are widespread in producer strains. Therefore, prudence must be exercised if and when bacteriocins 
and related products are utilised clinically to avoid the spread of resistance and loss of efficacy. 
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